Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Rajkumar

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Journal of Neuro-Oncology|February 24, 2001
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent gliomaS V Rajkumar, J M Reid, P J Novotny, et al.
Leukemia|May 13, 2015
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapyM Alhaj Moustafa, S V Rajkumar, A Dispenzieri, et al.
Blood|September 25, 2001
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosisS R Hayman, R J Bailey, S M Jalal, et al.
Bone Marrow Transplantation|September 4, 2003
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myelomaI M Ghobrial, A Dispenzieri, K L Bundy, et al.
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
Bone Marrow Transplantation|July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or olderE Muchtar, D Dingli, S Kumar, et al.
Leukemia|July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSJ A Katzmann, R Clark, R A Kyle, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Journal of Neuro-Oncology|February 24, 2001
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent gliomaS V Rajkumar, J M Reid, P J Novotny, et al.
Leukemia|May 13, 2015
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapyM Alhaj Moustafa, S V Rajkumar, A Dispenzieri, et al.
Blood|September 25, 2001
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosisS R Hayman, R J Bailey, S M Jalal, et al.
Bone Marrow Transplantation|September 4, 2003
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myelomaI M Ghobrial, A Dispenzieri, K L Bundy, et al.
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
Bone Marrow Transplantation|July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or olderE Muchtar, D Dingli, S Kumar, et al.
Leukemia|July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSJ A Katzmann, R Clark, R A Kyle, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Pageof 17